Scholarlink

Background <p>Artemether-lumefantrine (AL) was introduced into Ghana’s antimalarial medicines policy in 2008 as an alternative to artesunate-amodiaquine (AS-AQ) for the treatment of uncomplicated malaria. Studies conducted between 2010 and 2021 had shown the efficacy of AL to be above 90%. This study aimed at determining the current efficacy of AL in 10 sentinel sites after 16&#xa0;years of its formal introduction as one of the first-line medicines for uncomplicated malaria in the country.</p> Methods <p>The study was conducted among febrile children aged 6&#xa0;months to 9&#xa0;years between August 2024 and January 2025 using the WHO protocol for surveillance of antimalarial drug efficacy and reported using the standardized antimalarial therapeutic efficacy reporting (STARTER) checklist. Children enrolled were followed-up for 28&#xa0;days. Parasite recrudescence and re-infections were determined using merozoite surface protein 1 (<i>msp1</i>), merozoite surface protein 2 (<i>msp2</i>), and one microsatellite (poly-α) in the recommended 3/3 PCR-genotyping approach.</p> Results <p>Out of 1387 suspected uncomplicated malaria cases screened, 747 met the inclusion criteria and were subsequently enrolled. Out of this, 738 completed their follow-up visits. PCR-uncorrected cure rates across the 10 sentinel sites ranged between 85.9% (95% CI 76.6–92.5) and 100% with a national rate of 96.3% (95% CI 94.7–97.6) whilst PCR-corrected cure rates ranged between 91.9% (95% CI 78.1–98.3) and 100% with a national rate of 98.9% (95% CI 97.8–99.5). No early treatment failures were observed at any of the sites. Also, no child enrolled was parasitaemic on Day 3.</p> Conclusions <p>AL has remained highly efficacious (&gt; 90%) in the treatment of uncomplicated malaria in Ghana, even after 16&#xa0;years of its formal introduction into the country’s antimalarial medicines policy. Preserving this high efficacy through strategies such as the deliberate implementation of multiple first-line therapy (MFT) has become critical, particularly as lumefantrine is needed for the development of non-artemisinin combination therapies in response to the spread of artemisinin resistance.</p> <p><i>Trial Registration</i> Pan African Clinical Trial Registry—PACTR202502791855505.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of artemether-lumefantrine combination for the treatment of uncomplicated Plasmodium falciparum malaria after 16 years of its introduction into Ghana’s antimalarial medicines policy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Benjamin Abuaku,
  • Paul Boateng,
  • Nancy Odurowah Duah-Quashie,
  • Nana Yaw Peprah,
  • Alexander Asamoah,
  • Sena Adzoa Matrevi,
  • Joel Idun-Acquah,
  • Eunice Obeng Amoako,
  • Esther Baafi,
  • Emmanuel Gyekye,
  • Nelly Amankrah-Yeboah,
  • Bernard Logonia,
  • Selassie Bruku,
  • Kwesi Tandoh,
  • Neils Quashie,
  • Felicia Owusu-Antwi,
  • Kwadwo Ansah Koram,
  • Paul Hilarius Abiwu,
  • Keziah Laurencia Malm

摘要

Background

Artemether-lumefantrine (AL) was introduced into Ghana’s antimalarial medicines policy in 2008 as an alternative to artesunate-amodiaquine (AS-AQ) for the treatment of uncomplicated malaria. Studies conducted between 2010 and 2021 had shown the efficacy of AL to be above 90%. This study aimed at determining the current efficacy of AL in 10 sentinel sites after 16 years of its formal introduction as one of the first-line medicines for uncomplicated malaria in the country.

Methods

The study was conducted among febrile children aged 6 months to 9 years between August 2024 and January 2025 using the WHO protocol for surveillance of antimalarial drug efficacy and reported using the standardized antimalarial therapeutic efficacy reporting (STARTER) checklist. Children enrolled were followed-up for 28 days. Parasite recrudescence and re-infections were determined using merozoite surface protein 1 (msp1), merozoite surface protein 2 (msp2), and one microsatellite (poly-α) in the recommended 3/3 PCR-genotyping approach.

Results

Out of 1387 suspected uncomplicated malaria cases screened, 747 met the inclusion criteria and were subsequently enrolled. Out of this, 738 completed their follow-up visits. PCR-uncorrected cure rates across the 10 sentinel sites ranged between 85.9% (95% CI 76.6–92.5) and 100% with a national rate of 96.3% (95% CI 94.7–97.6) whilst PCR-corrected cure rates ranged between 91.9% (95% CI 78.1–98.3) and 100% with a national rate of 98.9% (95% CI 97.8–99.5). No early treatment failures were observed at any of the sites. Also, no child enrolled was parasitaemic on Day 3.

Conclusions

AL has remained highly efficacious (> 90%) in the treatment of uncomplicated malaria in Ghana, even after 16 years of its formal introduction into the country’s antimalarial medicines policy. Preserving this high efficacy through strategies such as the deliberate implementation of multiple first-line therapy (MFT) has become critical, particularly as lumefantrine is needed for the development of non-artemisinin combination therapies in response to the spread of artemisinin resistance.

Trial Registration Pan African Clinical Trial Registry—PACTR202502791855505.